IZABRIGHT-Bladder01 trial: what clinicians have said so far
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
- NCT07106762 ↗
- Recruiting
- Bristol-Myers Squibb
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on IZABRIGHT-Bladder01 (izalontamab brengitecan in metastatic urothelial cancer with progression after immunotherapy) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IZABRIGHT-Bladder01 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 7 posts on X, typically up to 31 once built |
The trial
ClinicalTrials.gov- Official title
- IZABRIGHT-Bladder01: A Randomized, Open-label, Phase 2/3 Trial of Izalontamab Brengitecan Versus Platinum-based Chemotherapy for Metastatic Urothelial Cancer in Participants With Disease Progression on or After an Immunotherapy-based Treatment
- Phase
- Phase 2/Phase 3
- Status
- Recruiting
- Conditions
- Urothelial Cancer
- Interventions
- Iza-bren; Cisplatin; Gemcitabine; Carboplatin
- Arms
- Arm A · Experimental
- Arm B · Experimental
- Arm C · Active comparator
- Arm D · Experimental
- Arm E · Active comparator
- Enrollment
- 470 (estimated)
- Primary outcomes
- Phase 2: Recommended Phase 3 Dose (RP3D) of BMS-986507
- Phase 3: Progression-Free Survival (PFS)
- Phase 3: Overall Survival (OS)
- Sponsor
- Bristol-Myers Squibb
- Start
- Sep 30, 2025
- Primary completion
- Jan 26, 2029 (estimated)
- Results posted
- No
- Registry record
- NCT07106762 · updated Jul 29, 2026